Prosecution Insights
Prosecution Insights
16 pending office actions • 7 art units • 13 examiners • 0 of 16 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (12%) |
| §112 only | 4 (25%) |
| Double-patenting only | 1 (6%) |
| Double-patenting + other | 8 (50%) |
| Multi-statute (no §101) | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKELDING, ZACHARY S | 3 | 59.8% | +41.0% |
| PUTTLITZ, KARL J | 2 | 69.1% | +18.5% |
| XIAO, YAN | 1 | 67.8% | +51.6% |
| CHANDRA, GYAN | 1 | 71.3% | +27.4% |
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.5% |
| DARPOLOR, JOSEPHINE KEBBEH | 1 | 64.5% | +37.9% |
| YU, MISOOK | 1 | 38.9% | +17.7% |
| BRISTOL, LYNN ANNE | 1 | 63.6% | +39.7% |
| SALVOZA, M FRANCO G | 1 | 68.7% | +29.6% |
| MOSELEY II, NELSON B | 1 | 67.8% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | SKELDING, ZACHARY S | 117d overdue |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 5d overdue |
| 18478711 | ANTIBODIES BINDING TO CD30 AND CD3 | CHANDRA, GYAN | 4d overdue |
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | — |
| 18029472 | ANTIBODIES CAPABLE OF BINDING TO ROR2 AND BISPECIFIC ANTIBODIES BINDING TO ROR2 AND CD3 | KAUFMAN, CLAIRE M | — |
| 18025206 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | DARPOLOR, JOSEPHINE KEBBEH | — |
| 18025204 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA | YU, MISOOK | — |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1644 | 5 |
| 1642 | 3 |
| 1674 | 2 |
| 1646 | 2 |
| 1641 | 1 |
| 1643 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18500799 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | XIAO, YAN | — | DP | Non-Final OA | — | Pending | Nov 02, 2023 |
| 18478711 | ANTIBODIES BINDING TO CD30 AND CD3 | CHANDRA, GYAN | 1674 | §112Other | Final Rejection | 4d overdue | Pending | Sep 29, 2023 |
| 18029472 | ANTIBODIES CAPABLE OF BINDING TO ROR2 AND BISPECIFIC ANTIBODIES BINDING TO ROR2 AND CD3 | KAUFMAN, CLAIRE M | 1674 | §112 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18025206 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | DARPOLOR, JOSEPHINE KEBBEH | 1642 | §103DP | Final Rejection | — | Pending | Mar 08, 2023 |
| 18025204 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA | YU, MISOOK | 1641 | §103§112DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 18025203 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | BRISTOL, LYNN ANNE | 1643 | §112DPOther | Final Rejection | — | Pending | Mar 08, 2023 |
| 18023808 | ANTIBODY THERAPY | SALVOZA, M FRANCO G | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18109708 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | §102§112Other | Non-Final OA | — | Pending | Feb 14, 2023 |
| 18160386 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jan 27, 2023 |
| 18160391 | BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA | PETRASH, HILARY ANN | 1644 | §103§112DP | Non-Final OA | — | Pending | Jan 27, 2023 |
| 18010783 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER | BELYAVSKYI, MICHAIL A | 1644 | §103DP | Final Rejection | 7d | Pending | Dec 15, 2022 |
| 17957302 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 1646 | §103Other | Non-Final OA | 5d overdue | Pending | Sep 30, 2022 |
| 17714735 | MULTISPECIFIC ANTIGEN-BINDING MOLECULE WITH IMPROVED INTERNALIZATION CHARACTERISTICS | GODDARD, LAURA B | 1642 | §112 | Non-Final OA | — | Pending | Apr 06, 2022 |
| 16891796 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | PUTTLITZ, KARL J | 1646 | DPOther | Final Rejection | — | Pending | Jun 03, 2020 |
| 16702996 | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | SKELDING, ZACHARY S | 1644 | §112DP | Non-Final OA | 117d overdue | Pending | Dec 04, 2019 |
| 16582428 | HUMANIZED OR CHIMERIC CD3 ANTIBODIES | SKELDING, ZACHARY S | 1644 | §112Other | Non-Final OA | — | Pending | Sep 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial